Shore Capital is delighted to have acted as Sole Financial Adviser and Broker on Glantus Holdings plc’s (AIM:GLAN) £17.8m recommended […]

Shore Capital is delighted to have acted as Financial Adviser and Broker on Goodwin PLC’s (LSE:GDWN) £8.64m Tender Offer. With […]

Shore Capital is delighted to have acted as Nominated Adviser, Broker and Bookrunner on FireAngel Safety Technology Group’s (AIM:FA) £6.1m […]

Shore Capital is delighted to have acted as Financial Adviser, Broker and Bookrunner on an oversubscribed £12 million Placing and […]

We are delighted to have been appointed as Joint Broker to Accrol Group Holdings plc (AIM: ACRL), adding to Shore […]

We are delighted to have been appointed as Nomad and Sole Broker to musicMagpie plc (AIM:MMAG).  Stockport based musicMagpie plc […]

Shore Capital is delighted to have acted as Joint Broker and Joint Bookrunner for Destiny Pharma plc (AIM: DEST) on […]

Shore Capital is delighted to have been appointed as Nominated Adviser and Joint Broker to Portmeirion Group plc (AIM: PMP). […]

Shore Capital is delighted to have acted as Joint Bookrunner for OnTheMarket plc (AIM: OTMP) on a secondary placing of […]

Shore Capital is delighted to have acted as Joint Bookrunner for Petro Matad Limited (AIM: MATD) on a US$6m placing […]

Shore Capital is delighted to have acted as Nominated Adviser and UK Joint Bookrunner for Touchstone Exploration (AIM:TXP) on an […]

Shore Capital is delighted to have acted as Nomad, Broker and Sole Bookrunner for Helios Underwriting plc (AIM: HUW) on […]

Shore Capital is delighted to be appointed as Joint Corporate Broker to Destiny Pharma plc (AIM: DEST). Destiny Pharma is […]

Shore Capital is delighted to have acted as Joint Corporate Broker and Joint Bookrunner for ThomasLloyd Energy Impact Trust plc […]

Shore Capital is delighted to have acted as Joint Bookrunner for Eagle Eye Solutions Group (AIM: EYE) on a £7m […]

Shore Capital is delighted to be appointed as joint Corporate Broker to SSP Group plc (LON: SSPG). With a market capitalisation […]

Oxford BioDynamics (AIM:OBD) a biotechnology company developing targeted clinical diagnostic tests for immune health based on the EpiSwitch® 3D genomics […]

H&T Group (AIM:HAT) has successfully raised £16.9m via an oversubscribed placing and retail offer, with Shore Capital acting as Sole […]